Abstract
The notion of using specific oligonucleotides for the modulation of gene expression surfaced nearly two decades ago when DNA oligonucleotides were used to inhibit Rous sarcoma virus replication and cell transformation (Zamenick 1978). The basic idea behind the use of antisense molecules is quite simple. An oligonucleotide chain containing bases complementary to a given target (sense) sequence can bind to this target sequence, and thus inhibit its processing, through the interactions defined by the Watson and Crick base pairing rules. These rules state that a guanosine must always base pair with a cytosine, while a tyrosine must base pair with an adenosine. Thus, once the sequence of a target gene is known, an antisense molecule can be designed which specifically binds to this gene alone. The initial antisense molecules were oligodeoxynucleotide sequences targeted to mRNA molecules. However, recent advances in molecular biology have widened the spectrum of antisense compounds to include RNA oligos targeted against RNA, DNA oligos targeted against DNA (termed antigenes) and either DNA or RNA oligos which bind to and inhibit the function of peptides and proteins (termed aptamers) (for reviews see Ma and Calvo 1996; Scanlon et al. 1995; Wagner 1994, 1995; Zhang 1996).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Askari F, McDonnell W (1996) Antisense-oligonucleotide therapy. New Eng J Med 334:316–318
Bennett C, Dean N, Ecker D, Monia B (1995) Pharmacology of antisense therapeutic agents. In: Agrawal S (ed) Methods in molecular medicine: antisense therapeutics. Human,Totowa, New Jersey, pp 13–46
Bergan R, Connell Y, Fahmy B, Neckers L (1993) Electroporation enhances c-myc antisense oligonucleotide efficacy. Nucleic Acids Res 21(15):3567–3573
Bergan R, Graham M, Crooke M, Crooke S (1995) In vitro pharmokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462–473
Crooke R, Graham M, Crooke M, Crooke S (1995) In vitro pharmokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462–473
Editorial (1994) Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 4:67–69
Editorial (1995) Delivery of oligonucleotides and polynucleotides. J Drug Target 3:185–190
Gerwitz A, Stein C, Glazer P (1996) Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 93:3161–3163
Ma L, Calvo F (1996) Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol 10:97–115
Scanlon K, Ohta Y, Ishida H, Kijma H, Ohkawa T, Kaminski A, Tsai J, Horng G, Kashani-Sabet M (1995) Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288–1296
Sharma H, Narayanan R (1995) The therapeutic potential of antisense oligonucleoti-des. BioEssays 17(12):1055–1063
Skotzko M, Wu L, Anderson W, Gordon E, Hall F (1995) Retroviral Vector-mediated gene transfer of antisense cyclin Gl (CYCG1) inhibits proliferation of human oste-ogenic sarcoma cells. Cancer Res 55:5493–5498
Stein C (1995) Does antisense exist. Nature Med 11:1119–1121
Wagner R (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333–335
Wagner R (1995) The state of the art in antisense research. Nature Med 11:1116–1118
Zamecnik P, Stephenson M (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a sepcific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 1:280–284
Zhang W (1996) Antisense oncogene and tumor suppressor gene therapy of cancer. J Mol Med 74:191–204
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Byrne, D., Daly, C., Clynes, M. (1998). Antisense Methods in Cell Culture. In: Clynes, M. (eds) Animal Cell Culture Techniques. Springer Lab Manual. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80412-0_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-80412-0_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63008-1
Online ISBN: 978-3-642-80412-0
eBook Packages: Springer Book Archive